Trial Outcomes & Findings for Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression (NCT NCT00926393)
NCT ID: NCT00926393
Last Updated: 2011-05-11
Results Overview
The Modified Bond-Lader Visual Analog Scale (VAS) uses a 100 mm line, each with a set of opposing adjectives at either end:Alert (=0) - Drowsy (=100); If patient is sleeping the Bond-Lader VAS will be assign a score of 100.
COMPLETED
PHASE4
139 participants
At 1 hour post-dose, Day 2 (50 mg)
2011-05-11
Participant Flow
A 7-day, inpatient, multicenter, double-blind, double-dummy, randomized, parallel group, Phase IV study was done to compare the tolerability of quetiapine IR with quetiapine XR during initial dose escalation in patients with bipolar depression. In total 139 patients were randomized in 15 centers in the USA between June and August 2009.
Patients must have DSM-IV-TR documented bipolar I or bipolar II, most recent episode depressed, and outpatient status at enrollment . Patients must not have another current, major disorder that is symptomatic or has required treatment within 6 months of enrollment.
Participant milestones
| Measure |
Quetiapine IR
Quetiapine fumarate Immediate Release
|
Quetiapine XR
Quetiapine fumarate Extended Release
|
|---|---|---|
|
Overall Study
STARTED
|
69
|
70
|
|
Overall Study
COMPLETED
|
67
|
67
|
|
Overall Study
NOT COMPLETED
|
2
|
3
|
Reasons for withdrawal
| Measure |
Quetiapine IR
Quetiapine fumarate Immediate Release
|
Quetiapine XR
Quetiapine fumarate Extended Release
|
|---|---|---|
|
Overall Study
Withdrawal by Subject
|
1
|
2
|
|
Overall Study
Adverse Event
|
1
|
1
|
Baseline Characteristics
Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression
Baseline characteristics by cohort
| Measure |
Quetiapine IR
n=69 Participants
Quetiapine fumarate Immediate Release
|
Quetiapine XR
n=70 Participants
Quetiapine fumarate Extended Release
|
Total
n=139 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Customized
18-39
|
28 Participants
n=99 Participants
|
31 Participants
n=107 Participants
|
59 Participants
n=206 Participants
|
|
Age, Customized
40-50
|
41 Participants
n=99 Participants
|
39 Participants
n=107 Participants
|
80 Participants
n=206 Participants
|
|
Sex: Female, Male
Female
|
32 Participants
n=99 Participants
|
34 Participants
n=107 Participants
|
66 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
37 Participants
n=99 Participants
|
36 Participants
n=107 Participants
|
73 Participants
n=206 Participants
|
PRIMARY outcome
Timeframe: At 1 hour post-dose, Day 2 (50 mg)Population: The modified intent-to-treat (MITT) analysis data set included all randomized patients who received study treatment, classified according to their randomized treatment and provided the Modified Bond-Lader VAS score at baseline (pre-dose at Day 1 or Day 2) and at least 1 hour after 50 mg dose administration.
The Modified Bond-Lader Visual Analog Scale (VAS) uses a 100 mm line, each with a set of opposing adjectives at either end:Alert (=0) - Drowsy (=100); If patient is sleeping the Bond-Lader VAS will be assign a score of 100.
Outcome measures
| Measure |
Quetiapine IR
n=65 Participants
Quetiapine fumarate Immediate Release
|
Quetiapine XR
n=69 Participants
Quetiapine fumarate Extended Release
|
|---|---|---|
|
Modified Bond-Lader Visual Analog Scale Score After 50-mg Dose (Day 2)
|
45.022 units on scale
Interval 38.287 to 51.758
|
32.472 units on scale
Interval 25.935 to 39.009
|
SECONDARY outcome
Timeframe: At 1 hour post-dose, Day 3 (100 mg)Population: The modified intent-to-treat (MITT) analysis data set included all randomized patients who received study treatment, classified according to their randomized treatment and provided the Modified Bond-Lader VAS score at baseline (pre-dose at Day 1 or Day 2) and at least 1 hour after 50 mg dose administration.
The Modified Bond-Lader Visual Analog Scale (VAS) uses a 100 mm line, each with a set of opposing adjectives at either end:Alert (=0) - Drowsy (=100); If patient is sleeping the Bond-Lader VAS will be assign a score of 100.
Outcome measures
| Measure |
Quetiapine IR
n=65 Participants
Quetiapine fumarate Immediate Release
|
Quetiapine XR
n=69 Participants
Quetiapine fumarate Extended Release
|
|---|---|---|
|
Modified Bond-Lader Visual Analog Scale Score After 100-mg Dose (Day 3)
|
51.521 units on scale
Standard Error 3.341 • Interval 3.341 to
|
29.146 units on scale
Standard Error 3.239 • Interval 3.239 to
|
SECONDARY outcome
Timeframe: At 1 hour post-dose, Day 4 (200 mg)Population: The modified intent-to-treat (MITT) analysis data set included all randomized patients who received study treatment, classified according to their randomized treatment and provided the Modified Bond-Lader VAS score at baseline (pre-dose at Day 1 or Day 2) and at least 1 hour after 50 mg dose administration.
The Modified Bond-Lader Visual Analog Scale (VAS) uses a 100 mm line, each with a set of opposing adjectives at either end:Alert (=0) - Drowsy (=100); If patient is sleeping the Bond-Lader VAS will be assign a score of 100.
Outcome measures
| Measure |
Quetiapine IR
n=65 Participants
Quetiapine fumarate Immediate Release
|
Quetiapine XR
n=69 Participants
Quetiapine fumarate Extended Release
|
|---|---|---|
|
Modified Bond-Lader Visual Analog Scale Score After 200-mg Dose (Day 4)
|
48.336 units on scale
Standard Error 3.703 • Interval 3.703 to
|
30.130 units on scale
Standard Error 3.609 • Interval 3.609 to
|
SECONDARY outcome
Timeframe: At 1 hour post-dose, Day 5 (300 mg)Population: The modified intent-to-treat (MITT) analysis data set included all randomized patients who received study treatment, classified according to their randomized treatment and provided the Modified Bond-Lader VAS score at baseline (pre-dose at Day 1 or Day 2) and at least 1 hour after 50 mg dose administration.
The Modified Bond-Lader Visual Analog Scale (VAS) uses a 100 mm line, each with a set of opposing adjectives at either end:Alert (=0) - Drowsy (=100); If patient is sleeping the Bond-Lader VAS will be assign a score of 100.
Outcome measures
| Measure |
Quetiapine IR
n=65 Participants
Quetiapine fumarate Immediate Release
|
Quetiapine XR
n=69 Participants
Quetiapine fumarate Extended Release
|
|---|---|---|
|
Modified Bond-Lader Visual Analog Scale Score After 300-mg Dose (Day 5)
|
49.414 units on scale
Standard Error 4.347 • Interval 4.347 to
|
32.626 units on scale
Standard Error 4.258 • Interval 4.258 to
|
SECONDARY outcome
Timeframe: At 1 hour post-dose, Day 6 (300 mg)Population: The modified intent-to-treat (MITT) analysis data set included all randomized patients who received study treatment, classified according to their randomized treatment and provided the Modified Bond-Lader VAS score at baseline (pre-dose at Day 1 or Day 2) and at least 1 hour after 50 mg dose administration.
The Modified Bond-Lader Visual Analog Scale (VAS) uses a 100 mm line, each with a set of opposing adjectives at either end:Alert (=0) - Drowsy (=100); If patient is sleeping the Bond-Lader VAS will be assign a score of 100.
Outcome measures
| Measure |
Quetiapine IR
n=65 Participants
Quetiapine fumarate Immediate Release
|
Quetiapine XR
n=69 Participants
Quetiapine fumarate Extended Release
|
|---|---|---|
|
Modified Bond-Lader Visual Analog Scale Score After 300-mg Dose (Day 6)
|
48.959 units on scale
Standard Error 4.015 • Interval 4.015 to
|
30.144 units on scale
Standard Error 3.910 • Interval 3.91 to
|
SECONDARY outcome
Timeframe: During Day 2 (50 mg)Population: The modified intent-to-treat (MITT) analysis data set included all randomized patients who received study treatment, classified according to their randomized treatment and provided the Modified Bond-Lader VAS score at baseline (pre-dose at Day 1 or Day 2) and at least 1 hour after 50 mg dose administration.
The Maximum Intensity Modified Bond-Lader VAS after dose (MaxIntVAS) is calculated as maximum possible value of VAS during that day at any from 1, 2, 3, 4, 5, 12, 13, 14 hours post-dose assessments
Outcome measures
| Measure |
Quetiapine IR
n=65 Participants
Quetiapine fumarate Immediate Release
|
Quetiapine XR
n=69 Participants
Quetiapine fumarate Extended Release
|
|---|---|---|
|
Maximum Intensity Modified Bond-Lader Visual Analog Scale Score
|
99.929 units on scale
Standard Error 1.353 • Interval 1.353 to
|
96.937 units on scale
Standard Error 1.313 • Interval 1.313 to
|
SECONDARY outcome
Timeframe: During Day 2 (50 mg)Population: The modified intent-to-treat (MITT) analysis data set included all randomized patients who received study treatment, classified according to their randomized treatment and provided the Modified Bond-Lader VAS score at baseline (pre-dose at Day 1 or Day 2) and at least 1 hour after 50 mg dose administration.
Time (Tmax) to Maximum Intensity Modified Bond-Lader VAS after dose is corresponding assessment time (one from 1, 2, 3, 4, 5, 12, 13, 14 hours post-dose) of MaxIntVas
Outcome measures
| Measure |
Quetiapine IR
n=65 Participants
Quetiapine fumarate Immediate Release
|
Quetiapine XR
n=69 Participants
Quetiapine fumarate Extended Release
|
|---|---|---|
|
Time to Maximum Intensity Modified Bond-Lader Visual Analog Scale Score
|
3.685 Hours
Standard Error 0.246 • Interval 0.246 to
|
4.254 Hours
Standard Error 0.239 • Interval 0.239 to
|
SECONDARY outcome
Timeframe: During Day 2 (50 mg)Population: The randomized safety analysis data set included all patients who received at 1 dose of randomized study treatment during the Randomized treatment Phase, classified according to actual treatment taken.
Area under the Modified Bond-Lader VAS-time curve is calculated by the linear trapezoidal formula which equals sum of (Ck+Ck+1)/2 multiplied by the time interval between k and k+1 observations, where Ck and Ck+1 are the corresponding the intensity of sedation evaluations measured by the Modified Bond-Lader VAS from 1 to 14 hours post-dose
Outcome measures
| Measure |
Quetiapine IR
n=65 Participants
Quetiapine fumarate Immediate Release
|
Quetiapine XR
n=69 Participants
Quetiapine fumarate Extended Release
|
|---|---|---|
|
Area Under the Modified Bond-Lader Visual Analog Scale-time Curve
|
1061.12 mm * hour
Standard Error 31.559 • Interval 31.559 to
|
988.842 mm * hour
Standard Error 30.612 • Interval 30.612 to
|
SECONDARY outcome
Timeframe: Randomization to Day 7Population: The randomized safety analysis data set included all patients who received at 1 dose of randomized study treatment during the Randomized treatment Phase, classified according to actual treatment taken.
SAS total score is the sum of the 10 individual-item scores (range:0-40), with the score for each item ranging from 0 to 4, higher scores indicate greater severity of Parkinsonian symptoms. Change : total score at day 7 minus total score at randomization. Increase in Change of total score indicates an increase in extrapyramidal motor symptoms.
Outcome measures
| Measure |
Quetiapine IR
n=69 Participants
Quetiapine fumarate Immediate Release
|
Quetiapine XR
n=70 Participants
Quetiapine fumarate Extended Release
|
|---|---|---|
|
Change in Simpson-Angus Scale (SAS) Total Score
|
-0.1 units on scale
Standard Deviation 0.8
|
0.1 units on scale
Standard Deviation 0.5
|
SECONDARY outcome
Timeframe: Randomization to Day 7Population: The randomized safety analysis data set included all patients who received at 1 dose of randomized study treatment during the Randomized treatment Phase, classified according to actual treatment taken.
BARS global score is the 4th individual-item score on the BARS scale,the Global Assessment of Akathisia, with the score ranging from 0 to 5. Change : score at day 7 minus score at randomization. Increase in Change of BARS global score indicates an increase in akathisia.
Outcome measures
| Measure |
Quetiapine IR
n=69 Participants
Quetiapine fumarate Immediate Release
|
Quetiapine XR
n=70 Participants
Quetiapine fumarate Extended Release
|
|---|---|---|
|
Change in Barnes Akathisia Rating Scale (BARS) Global Score
|
-0.07 units on scale
Standard Deviation 0.43
|
-0.09 units on scale
Standard Deviation 0.45
|
SECONDARY outcome
Timeframe: Randomization to Day 7Population: The randomized safety analysis data set included all patients who received at 1 dose of randomized study treatment during the Randomized treatment Phase, classified according to actual treatment taken.
AIMS total score is the sum of the 10 individual-item scores (range:0-40), with the score for each item ranging from 0 to 4. Change : total score at day 7 minus total score at randomization. Increase in Change of total score indicates an increase in abnormal voluntary movements.
Outcome measures
| Measure |
Quetiapine IR
n=69 Participants
Quetiapine fumarate Immediate Release
|
Quetiapine XR
n=70 Participants
Quetiapine fumarate Extended Release
|
|---|---|---|
|
Change in Abnormal Involuntary Movement Scale (AIMS) Total Score
|
-0.01 units on scale
Standard Deviation 0.3
|
-0.04 units on scale
Standard Deviation 0.4
|
SECONDARY outcome
Timeframe: From start of the study treatment to last dose plus 30 daysPopulation: The randomized safety analysis data set included all patients who received at 1 dose of randomized study treatment during the Randomized treatment Phase, classified according to actual treatment taken.
Number of patients with adverse events potentially associated with EPS collected by MedDRA Preferred Terms as akathisia, extrapyramidal disorder, restlessness
Outcome measures
| Measure |
Quetiapine IR
n=69 Participants
Quetiapine fumarate Immediate Release
|
Quetiapine XR
n=70 Participants
Quetiapine fumarate Extended Release
|
|---|---|---|
|
Number of Patients With Potential Extrapyramidal Symptoms (EPS)
|
8 Patients
|
2 Patients
|
SECONDARY outcome
Timeframe: From start of the study treatment to last dose plus 30 daysNumber of patients with adverse events potentially associated with somnolence collected by MedDRA Preferred Terms as lethargy, sedation, somnolence
Outcome measures
| Measure |
Quetiapine IR
n=69 Participants
Quetiapine fumarate Immediate Release
|
Quetiapine XR
n=70 Participants
Quetiapine fumarate Extended Release
|
|---|---|---|
|
Number of Patients With Potential Somnolence
|
11 Patients
|
12 Patients
|
Adverse Events
Quetiapine IR
Quetiapine XR
Serious adverse events
| Measure |
Quetiapine IR
n=69 participants at risk
Quetiapine fumarate Immediate Release
|
Quetiapine XR
n=70 participants at risk
Quetiapine fumarate Extended Release
|
|---|---|---|
|
Nervous system disorders
Convulsion
|
0.00%
0/69
|
1.4%
1/70
|
|
Psychiatric disorders
Depression
|
0.00%
0/69
|
1.4%
1/70
|
|
Psychiatric disorders
Suicide Attempt
|
0.00%
0/69
|
1.4%
1/70
|
Other adverse events
| Measure |
Quetiapine IR
n=69 participants at risk
Quetiapine fumarate Immediate Release
|
Quetiapine XR
n=70 participants at risk
Quetiapine fumarate Extended Release
|
|---|---|---|
|
Gastrointestinal disorders
Dry Mouth
|
13.0%
9/69
|
21.4%
15/70
|
|
Metabolism and nutrition disorders
Increased Appetite
|
15.9%
11/69
|
15.7%
11/70
|
|
Nervous system disorders
Dizziness
|
15.9%
11/69
|
5.7%
4/70
|
|
Nervous system disorders
Headache
|
11.6%
8/69
|
5.7%
4/70
|
|
Nervous system disorders
Somnolence
|
7.2%
5/69
|
10.0%
7/70
|
|
General disorders
Fatigue
|
4.3%
3/69
|
8.6%
6/70
|
|
Nervous system disorders
Sedation
|
5.8%
4/69
|
7.1%
5/70
|
|
Cardiac disorders
Tachycardia
|
8.7%
6/69
|
4.3%
3/70
|
|
Nervous system disorders
Akathisia
|
5.8%
4/69
|
1.4%
1/70
|
|
Gastrointestinal disorders
Nausea
|
1.4%
1/69
|
5.7%
4/70
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee The PI agrees to collaborate in good faith with AstraZeneca with regards to the contents and formation of any publication or disclosure to be made by the PI and to pay due consideration to the comments, views and opinions offered by AstraZeneca
- Publication restrictions are in place
Restriction type: OTHER